Tonix Pharmaceuticals to Present Poster on Tonmya at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting
CHATHAM, N.J., March 03, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated, commercial biotechnology company, announced today that a poster on Tonmya™ (cyclobenzaprine HCl sublingual tablets), which was investigated as TNX-102 SL, will be presented at the 2026 American Academy of Pain Medicine (AAPM) PainConnect Annual Meeting, being held March 5–8, 2026, in Salt Lake City, Utah.
Poster Presentation Details
Title: Treatment with TNX-102 SL Produces Clinically Meaningful Improvements in Patient-Centered Outcomes in Fibromyalgia
Poster #: 50
Date: March 6, 2026 at 4:55 PM ET
Conference: 2026 AAPM PainConnect Annual Meeting
Location: Salt Lake City, Utah
Presenter: Errol Gould, PhD, Vice President, Medical Affairs of Tonix Pharma
Tonix Pharmaceuticals Holding Corp.*
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA
* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
River Price Surges 31% as PIPPIN Crashes 38% — What’s Next for These Cryptos?

Bitcoin ETF Flows Flip Green After Record $8.9B Drawdown: Why Is the Money Coming Back?
Trump urges passage of U.S. Clarity Act, attacks banks for 'undercutting' GENIUS

WTI climbs to $76.00, eyes one-year high amid rising tensions in the Middle East
